文献速递消化内镜消化道肿瘤与早癌

冷冻球囊消融系统治疗内镜切除后瘢痕上浅表性食管鳞状细胞癌的前瞻性多中心试验:CRYO-SCAR研究(EPOC1902)

Prospective multicenter trial of the cryoballoon ablation system for superficial esophageal squamous cell carcinoma on post-endoscopic resection scars: a CRYO-SCAR study (EPOC1902).
PubMed 文献 · Gastrointest Endosc · 2024-02-29

这项在日本2家三级转诊中心开展的前瞻性研究,评估冷冻球囊消融系统(CBAS)治疗内镜切除后瘢痕上内镜诊断为T1a浅表性食管鳞状细胞癌(SESCC)的疗效与安全性。2020年10月至2021年10月共15例患者17处病变接受冷冻消融,其中2处需重复消融,独立中心评估委员会评估的原发灶及全部病变局部完全缓解率均为100%,技术成功率94.7%(18/19),中位随访14.3个月期间未报告复发、死亡或严重治疗相关不良事件。

要点

  • 15例患者17处病变接受冷冻球囊消融,独立中心评估的局部完全缓解率100%。
  • 技术成功率94.7%(18/19),中位手术时间9分钟,最高疼痛评分3分。
  • 中位随访14.3个月,未报告复发、死亡或严重治疗相关不良事件。

核心结论

  • CBAS对于内镜切除后瘢痕上的SESCC可能是安全有效的方法,是传统内镜治疗的一种令人鼓舞的替代选择。

研究设计与样本

  • 前瞻性研究,在日本2家三级转诊中心开展,纳入内镜诊断为内镜切除后瘢痕上T1a SESCC的患者,采用聚焦CBAS进行冷冻消融,主要终点为首次冷冻消融后48周由独立中心评估委员会评估的原发病灶局部完全缓解率。

主要发现

  • 2020年10月至2021年10月,15例患者17处病变接受冷冻消融,其中2处需重复冷冻消融。
  • 独立中心评估委员会评估的原发灶及全部病变局部完全缓解率均为100%,内镜医师评估与之一致。
  • 中位手术时间9分钟,8例患者无疼痛,数字评分量表(1至10分)报告的最高疼痛评分为3分。
  • 技术成功率为94.7%(18/19)。
  • 中位随访14.3个月期间,未报告复发、死亡或严重治疗相关不良事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Endoscopic resection is a minimally invasive treatment for superficial esophageal squamous cell carcinoma (SESCC). Post-endoscopic resection scars complicate en-bloc resection, even with advanced techniques, such as endoscopic submucosal dissection. The cryoballoon ablation system (CBAS) effectively manages Barrett's esophagus but has limited evidence in SESCC treatment, particularly on post-endoscopic resection scars. This study aimed to evaluate the efficacy and safety of the CBAS for treating SESCC on post-endoscopic resection scars. METHODS: This prospective study was conducted at 2 tertiary referral centers in Japan in patients endoscopically diagnosed with T1a SESCC on the post-endoscopic resection scar. Focal CBAS was used for cryoablation, with specific criteria for lesion selection and treatment method. The primary endpoint was the rate of local complete response (L-CR) of the primary lesion 48 weeks after the first cryoablation as evaluated by an independent central evaluation committee. RESULTS: From October 2020 to October 2021, 15 patients with 17 lesions underwent cryoablation, with 2 requiring repeat cryoablation. The L-CR rate for primary and all lesions evaluated by the central evaluation committee was 100%. The endoscopist's evaluation was consistent with these results. The median procedure time was 9 minutes. Eight patients experienced no pain, and the highest pain score reported on a numeric rating scale from 1 to 10 was 3. The technical success rate was 94.7% (18/19). Throughout the median follow-up period of 14.3 months, recurrences, deaths, or severe treatment-related adverse events were not reported. CONCLUSIONS: CBAS is a potentially safe and effective approach for SESCC on post-endoscopic resection scars and represents an encouraging alternative to traditional endoscopic treatments. (Clinical trial registration numbers: NCT03097666 and jRCT1080225331.).

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Sunakawa H, Yoda Y, Nonaka S, et al. Prospective multicenter trial of the cryoballoon ablation system for superficial esophageal squamous cell carcinoma on post-endoscopic resection scars: a CRYO-SCAR study (EPOC1902). Gastrointest Endosc. 2024. PMID: 38431103. doi:10.1016/j.gie.2024.02.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。